Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum Lp815
- Development stage
- Unknown
- Lead developer
- Verb Biotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum Lp815 is a probiotic bacterial strain identified for its high capacity to produce gamma-aminobutyric acid (GABA) within the human gastrointestinal tract. Developed by Lallemand Health Solutions, this live biotherapeutic product is designed to modulate the GABAergic system via the gut-brain axis. It is currently being evaluated in Phase 2 clinical trials for the treatment of mild to moderate anxiety and sleep disturbances, such as insomnia. Clinical studies (NCT06466603, NCT06789718) investigate its ability to reduce anxiety symptoms and improve both subjective and objective sleep outcomes through daily oral administration of 5 billion colony-forming units (CFU).
- Brand names
- GABA Probiotic LP815
- Other names
- L. plantarum Lp815
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on Lactiplantibacillus plantarum Lp815.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum Lp815.